1. Home
  2. DMAC vs TRAK Comparison

DMAC vs TRAK Comparison

Compare DMAC & TRAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DMAC
  • TRAK
  • Stock Information
  • Founded
  • DMAC 2000
  • TRAK 1990
  • Country
  • DMAC United States
  • TRAK United States
  • Employees
  • DMAC N/A
  • TRAK N/A
  • Industry
  • DMAC Biotechnology: Pharmaceutical Preparations
  • TRAK EDP Services
  • Sector
  • DMAC Health Care
  • TRAK Technology
  • Exchange
  • DMAC Nasdaq
  • TRAK Nasdaq
  • Market Cap
  • DMAC 310.1M
  • TRAK 275.7M
  • IPO Year
  • DMAC N/A
  • TRAK 1998
  • Fundamental
  • Price
  • DMAC $6.70
  • TRAK $15.46
  • Analyst Decision
  • DMAC Strong Buy
  • TRAK
  • Analyst Count
  • DMAC 3
  • TRAK 0
  • Target Price
  • DMAC $12.33
  • TRAK N/A
  • AVG Volume (30 Days)
  • DMAC 256.1K
  • TRAK 69.6K
  • Earning Date
  • DMAC 11-12-2025
  • TRAK 11-13-2025
  • Dividend Yield
  • DMAC N/A
  • TRAK 0.52%
  • EPS Growth
  • DMAC N/A
  • TRAK 20.69
  • EPS
  • DMAC N/A
  • TRAK 0.35
  • Revenue
  • DMAC N/A
  • TRAK $22,606,066.00
  • Revenue This Year
  • DMAC N/A
  • TRAK $12.20
  • Revenue Next Year
  • DMAC N/A
  • TRAK $20.00
  • P/E Ratio
  • DMAC N/A
  • TRAK $44.17
  • Revenue Growth
  • DMAC N/A
  • TRAK 10.53
  • 52 Week Low
  • DMAC $3.19
  • TRAK $13.87
  • 52 Week High
  • DMAC $7.49
  • TRAK $25.01
  • Technical
  • Relative Strength Index (RSI)
  • DMAC 48.84
  • TRAK 50.09
  • Support Level
  • DMAC $6.50
  • TRAK $14.08
  • Resistance Level
  • DMAC $7.10
  • TRAK $15.80
  • Average True Range (ATR)
  • DMAC 0.29
  • TRAK 0.56
  • MACD
  • DMAC -0.03
  • TRAK 0.16
  • Stochastic Oscillator
  • DMAC 32.90
  • TRAK 80.23

About DMAC DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

About TRAK ReposiTrak Inc.

ReposiTrak Inc is a software-as-a-service (SaaS) company based in Murray, Utah, specializing in supply chain management solutions for retailers, suppliers, and wholesalers, prominently in the food industry. The company offers three main product suites: ReposiTrak Compliance Management, ReposiTrak Traceability Network, and ReposiTrak Supply Chain Solutions. These platforms help customers comply with food safety regulations, manage supplier compliance documentation, trace products through the supply chain, and optimize supply chain operations. The company derives revenue from five sources: (i) subscription fees, (ii) transaction-based fees, (iii) professional services fees, (iv) license fees, and (v) hosting and maintenance fees.

Share on Social Networks: